INTRODUCTION

Ravulizumab (brand name Ultomiris) is a humanized monoclonal antibody (mAb) derived from eculizumab. Ravulizumab functions as a potent and selective complement 5 (C5) inhibitor and is used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

This plasmid is designed for expressing Ravulizumab in mammalian expression system such as HEK293 or Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-157
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Ravulizumab
Brand Name(s): Ultomiris
Classification: Monoclonal antibody (mAb)
Target: C5, C5D, C5a, C5b, CPAMD4, ECLZB, complement component 5, complement C5
Amino Acid Sequence: Identical to DB11580

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Ladwig PM, Willrich MAV. Ravulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry. J Mass Spectrom Adv Clin Lab. 2021 Aug 12;21:10-18.

[2] Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019 Sep 10;10:2040620719874728.

Contact Us